Mathijssen RHJ - Search Results

1

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.

Mout L, Moll JM, Chen M, de Morrée ES, de Ridder CMA, Gibson A, Stuurman D, Aghai A, Erkens-Schulze S, Mathijssen RHJ, Sparreboom A, de Wit R, Lolkema MP, van Weerden WM. Mout L, et al. Among authors: mathijssen rhj. Br J Cancer. 2020 Dec;123(12):1715-1719. doi: 10.1038/s41416-020-01105-y. Epub 2020 Sep 29. Br J Cancer. 2020. PMID: 32989230 Free PMC article.

2

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J. Sparreboom A, et al. Clin Cancer Res. 1998 Nov;4(11):2747-54. Clin Cancer Res. 1998. PMID: 9829738 Clinical Trial.

3

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

Mathijssen RH, van Alphen RJ, de Jonge MJ, Verweij J, de Bruijn P, Loos WJ, Nooter K, Vernillet L, Stoter G, Sparreboom A. Mathijssen RH, et al. Anticancer Drugs. 1999 Jan;10(1):9-16. doi: 10.1097/00001813-199901000-00002. Anticancer Drugs. 1999. PMID: 10194542 Clinical Trial.

4

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.

de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A. de Jonge MJ, et al. J Clin Oncol. 2000 Jan;18(1):195-203. doi: 10.1200/JCO.2000.18.1.195. J Clin Oncol. 2000. PMID: 10623710

5

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. Clin Cancer Res. 2001 Aug;7(8):2182-94. Clin Cancer Res. 2001. PMID: 11489791 Review.

6

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. J Clin Oncol. 2002 Jan 1;20(1):81-7. doi: 10.1200/JCO.2002.20.1.81. J Clin Oncol. 2002. PMID: 11773157

7

Altered irinotecan metabolism in a patient receiving phenytoin.

Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA. Mathijssen RH, et al. Anticancer Drugs. 2002 Feb;13(2):139-40. doi: 10.1097/00001813-200202000-00004. Anticancer Drugs. 2002. PMID: 11901305

8

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Mathijssen RH, Verweij J, Loos WJ, de Bruijn P, Nooter K, Sparreboom A. Mathijssen RH, et al. Br J Cancer. 2002 Jul 15;87(2):144-50. doi: 10.1038/sj.bjc.6600447. Br J Cancer. 2002. PMID: 12107833 Free PMC article.

9

Modulation of irinotecan metabolism by ketoconazole.

Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Kehrer DF, et al. J Clin Oncol. 2002 Jul 15;20(14):3122-9. doi: 10.1200/JCO.2002.08.177. J Clin Oncol. 2002. PMID: 12118026 Clinical Trial.

10

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Mathijssen RH, et al. Curr Cancer Drug Targets. 2002 Jun;2(2):103-23. doi: 10.2174/1568009023333890. Curr Cancer Drug Targets. 2002. PMID: 12188913 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

399 results

Search Page